Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Cost of Revenue (2019 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Cost of Revenue for 5 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 11.27% year-over-year to $1.5 million, compared with a TTM value of $16.5 million through Dec 2025, up 122.22%, and an annual FY2025 reading of $16.5 million, up 122.22% over the prior year.
  • Cost of Revenue was $1.5 million for Q4 2025 at Zevra Therapeutics, up from $1.2 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $12.4 million in Q2 2025 and bottomed at $22000.0 in Q4 2022.
  • Average Cost of Revenue over 5 years is $1.6 million, with a median of $952000.0 recorded in 2023.
  • The sharpest move saw Cost of Revenue crashed 62.71% in 2022, then surged 5477.27% in 2023.
  • Year by year, Cost of Revenue stood at $59000.0 in 2021, then plummeted by 62.71% to $22000.0 in 2022, then soared by 5477.27% to $1.2 million in 2023, then increased by 11.33% to $1.4 million in 2024, then increased by 11.27% to $1.5 million in 2025.
  • Business Quant data shows Cost of Revenue for ZVRA at $1.5 million in Q4 2025, $1.2 million in Q3 2025, and $12.4 million in Q2 2025.